Literature DB >> 31311301

Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl-Sirt1 pathway.

Yi Chen1, Xueyang Chen1, Jianguo Gao1, Chengfu Xu1, Ping Xu1, Youming Li1, Yong Zhu2, Chaohui Yu1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD), which has an unknown pathogenesis and lacks a curative treatment, is becoming more prevalent. A previous long noncoding RNA (lncRNA) profiling analysis revealed a potential role for fatty liver-related lncRNA 2 (FLRL2) in the pathogenesis of NAFLD. To further understand the role of FLRL2 in NAFLD and explore its therapeutic value, both in vivo and in vitro NAFLD models were constructed. Small interfering RNA and small hairpin RNA interference and adenovirus transfection were adopted to manipulate the expressions of FLRL2, aryl-hydrocarbon receptor nuclear translocator-like (Arntl), and sirtuin 1 (Sirt1) expression. Steatosis was evaluated through histologic staining with hematoxylin and eosin and oil red O and also by quantitative triglyceride measurements. FLRL2 is a widely distributed nuclear lncRNA that is down-regulated in NAFLD. Overexpression of FLRL2 resolved steatosis, lipogenesis, inflammation, and endoplasmic reticulum (ER) stress in NAFLD, and down-regulation of FLRL2 resulted in the opposite effects. Sequence analysis demonstrated that FLRL2 was located in the intronic region of the Arntl gene, and a luciferase assay showed transcriptional activation of the Arntl gene upon FLRL2 overexpression. A similar expression pattern and synergistic effect of Arntl manipulation was observed in NAFLD in vitro. Inhibition of Arntl partially reversed the steatosis amelioration induced by FLRL2 overexpression. Downstream Sirt1 was also inhibited in NAFLD and influenced by both FLRL2 and Arntl. In NAFLD mice, FLRL2 enhancement alleviated steatosis, activated the Arntl-Sirt1 axis, and inhibited lipogenesis, ER stress, and inflammation, providing preliminary evidence of the benefits of FLRL2-mediated gene therapy in NAFLD.-Chen, Y., Chen, X., Gao, J., Xu, C., Xu, P., Li, Y., Zhu, Y., Yu, C. Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl-Sirt1 pathway.

Entities:  

Keywords:  ER stress; NAFLD; hepatic inflammation; lipogenesis; lncRNA

Mesh:

Substances:

Year:  2019        PMID: 31311301     DOI: 10.1096/fj.201900643RRR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  11 in total

1.  The correlation between lncRNA NEAT1 and serum hepcidin in the peripheral blood of non-alcoholic fatty liver disease patients.

Authors:  Wenyong Zhou; Kongjun Qiu
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

Review 2.  Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment.

Authors:  Bo Zhu; Siu-Lung Chan; Jack Li; Kathryn Li; Hao Wu; Kui Cui; Hong Chen
Journal:  Front Cardiovasc Med       Date:  2021-09-07

3.  LncRNA-Gm9795 promotes inflammation in non-alcoholic steatohepatitis via NF-[Formula: see text]B/JNK pathway by endoplasmic reticulum stress.

Authors:  Liangying Ye; Dan Zhao; Yangzhi Xu; Jiaen Lin; Jiahui Xu; Kunyuan Wang; Zhanhui Ye; Yufeng Luo; Shiming Liu; Hui Yang
Journal:  J Transl Med       Date:  2021-03-09       Impact factor: 5.531

4.  Long-Term Effects of Very Low Dose Particle Radiation on Gene Expression in the Heart: Degenerative Disease Risks.

Authors:  Venkata Naga Srikanth Garikipati; Arsen Arakelyan; Eleanor A Blakely; Polly Y Chang; May M Truongcao; Maria Cimini; Vandana Malaredy; Anamika Bajpai; Sankar Addya; Malik Bisserier; Agnieszka Brojakowska; Abrisham Eskandari; Mary K Khlgatian; Lahouaria Hadri; Kenneth M Fish; Raj Kishore; David A Goukassian
Journal:  Cells       Date:  2021-02-13       Impact factor: 7.666

5.  Identifying Autophagy-Related lncRNAs and Potential ceRNA Networks in NAFLD.

Authors:  Ziyi Cao; Li Guan; RunZhi Yu; Jie Chen
Journal:  Front Genet       Date:  2022-06-30       Impact factor: 4.772

Review 6.  Noncoding RNAs as additional mediators of epigenetic regulation in nonalcoholic fatty liver disease.

Authors:  Mohamed Zaiou
Journal:  World J Gastroenterol       Date:  2022-09-21       Impact factor: 5.374

Review 7.  Long non-coding RNAs in metabolic disorders: pathogenetic relevance and potential biomarkers and therapeutic targets.

Authors:  B Alipoor; S Nikouei; F Rezaeinejad; S-N Malakooti-Dehkordi; Z Sabati; H Ghasemi
Journal:  J Endocrinol Invest       Date:  2021-04-01       Impact factor: 4.256

Review 8.  A comprehensive review of long non-coding RNAs in the pathogenesis and development of non-alcoholic fatty liver disease.

Authors:  Arezoo Gowhari Shabgah; Fatemeh Norouzi; Mahdiyeh Hedayati-Moghadam; Davood Soleimani; Naseh Pahlavani; Jamshid Gholizadeh Navashenaq
Journal:  Nutr Metab (Lond)       Date:  2021-02-23       Impact factor: 4.169

Review 9.  Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis.

Authors:  Vicneswarry Dorairaj; Siti Aishah Sulaiman; Nadiah Abu; Nor Azian Abdul Murad
Journal:  Biomedicines       Date:  2021-12-22

10.  Long non-coding RNA GAS5 contributes to the progression of nonalcoholic fatty liver disease by targeting the microRNA-29a-3p/NOTCH2 axis.

Authors:  Juanjuan Cui; Yang Wang; Haowei Xue
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.